# DAPERB 3,4-DiAminoPyridine and Electrophysiological Response in Brugada Syndrome

> **NCT00701077** · PHASE3 · TERMINATED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 5 (actual)

## Conditions studied

- Brugada Syndrome

## Interventions

- **DRUG:** 3,4-Di-amino-Pyridine
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00701077
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09-12
- **Primary completion:** 2010-03
- **Final completion:** 2010-04
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** recruitments issues
- **Last updated:** 2020-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00701077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00701077, "DAPERB 3,4-DiAminoPyridine and Electrophysiological Response in Brugada Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00701077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*